Mobile

A One-Year, Randomized, Open-Label, Parallel-Arm, Phase III Long-Term Safety Trial, with Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR* and Oxycodone CR in Subjects with Chronic Pain

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003482-14

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the trial is the evaluation of the safety profile of CG5503 PR base at doses ranging between 100 mg and 250 mg BID over long term exposure of up to one year.

Critère d'inclusion

  • Chronic pain due to knee or hip osteoarthritis or low back pain of benign origin

Liens